Affiliation:
1. Hospital Interzonal General de Agudos Profesor Dr. Rodolfo Rossi
2. Instituto de Efectividad Clínica y Sanitaria
3. Instituto de Oncología Ángel H. Roffo
4. Hospital Interzonal Especializado de Agudos y Crónicos San Juan de Dios
Abstract
Abstract
Purpose:
About 12,000 people are diagnosed with lung cancer (LC)each year in Argentina, and the diagnosis has a significant impact on the whole family. The objective of this study was to characterize the health-related Quality of life (HRQoL) and the economic impact in patients with LC and in their households.
Methods:
We undertook an observational cross-sectional study. Outcomes included the EuroQol EQ-5D-3L (health-related Quality of life), COST (financial toxicity), WPAI-GH (productivity loss), and out-of-pocket expenses in adults diagnosed with LC at two referral public health care centers In Argentina.
Results:
We included 101 consecutive patients (mean age 67.5 years; 55.4% men; 57.4% with advanced disease -stage III/IV-). The mean EQ-VAS was 68.8 (SD:18.3), with 82.2% describing fair or poor health. The most affected dimensions were anxiety/depression, pain, and activities of daily living. Patients reported an average 59% decrease in their ability to perform regular daily activities as measured by WPAI-GH. Around 54.5% decreased income due to the disease, with 19.8% of patients reporting losing their jobs. The economic productivity loss was estimated at USD 2,465 person/year.
About 70.3% of patients reported some degree of financial toxicity. The average out-of-pocket (OOP) expenditure was USD 100.38 person/month and represented 18.5% of household income, and the catastrophic expenditure was present in 37.1% of households. All outcomes were worse in patients with advanced disease.
Conclusions
Patients with NSCLCtreated in public hospitals in Argentina have significant health-related quality of life and economic impact, worsening in patients with advanced disease.
Publisher
Research Square Platform LLC
Reference27 articles.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, Nov. 2018, doi: 10.3322/caac.21492.
2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung H;Cancer J Clin,2021
3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA, “Non–Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship,” Mayo Clinic proceedings. Mayo Clinic, vol. 83, no. 5, p. 584, 2008, doi: 10.4065/83.5.584.
4. Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey;Morgensztern D;J Thorac Oncol,2010
5. NCCN Guidelines: Non-Small Cell Lung Cancer (Version 5.2021);Ettinger DS,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献